Exifull
Exifull, licence 80088231: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- Bonnevie EXIFULL, PurVit Folate-Iodine
- Licence holder
- Cambridge Pharma Inc.
- NPN or DIN-HM
- 80088231
- Status
- Active licence
- Licence date
- 6 September 2018
- Revision date
- Not provided
- Form
- Comprimé, enrobé par pellicule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Folate Source : Acide folique | 500.0 microgrammes | Not calculated |
| Iode Source : Iodure de potassium | 150.0 microgrammes | Not calculated |
| Vitamine B12 Source : Cyanocobalamine | 2.8 microgrammes | Not calculated |
Non-medicinal ingredients
Cellulose, Dioxyde de titane, Phosphate dicalcique, Laque Rouge 40, Stéarate de magnésium, Glycolate d'amidon sodique, Hydroxypropyl méthylcellulose, Bicarbonate de sodium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19.0 Année(s) | 1.0 Comprimé | 1.0 Tous les jours |
Uses authorised in Canada
Helps to reduce the risk of neural tube defects when taken daily at least three months prior to becoming pregnant and during early pregnancy. Helps to form red blood cells. Helps to support normal early development of the fetal brain and spinal cord. Helps in the function of the thyroid gland. Helps to maintain normal production of thyroid hormones. Helps in energy metabolism in the body. Helps in the normal function of the immune system.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 80088231
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.